ARV-102 is a novel investigational oral PROTAC designed to cross the blood-brain barrier and target LRRK2. While LRRK2 is primarily known for its role in PD, emerging evidence suggests that it ...

Arvinas will present preclinical data on ARV-393's potential in lymphoma treatment at the AACR Annual Meeting.

--Arvinas, Inc., a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ...